Site Content

https://www.fda.gov/media/154701/download

■ A new monoclonal antibody IM injection under EUA for pre-exposure prophylaxis in those aged 12+, weighing 40kg+ and:
■ Not currently infected with SARS-CoV-2 and have not had a known recent exposure
■ Have moderate-severe immune compromise and may not mount an adequate response to vaccination or cannot receive the vaccine due to history of severe adverse reaction to the COVID-19 vaccine and/or vaccine components. 

 Evusheld reduces the risk of symptomatic COVID-19 by 77% for up to 6 months after administration. 

 Evusheld constists of 2 gluteal injections done one right after the other followed by an hour of monitoring. You can expect to be at the pharmacy for about an hour and 15 minutes. 

 https://www.fda.gov/media/154702/download